Developing Therapies from the Protective Human Immune Response to Cancer
MabVax Therapeutics is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the clinical development of products to address unmet medical needs for the treatment of cancer. Our antibody HuMab-5B1, is a fully human IgG1 monoclonal antibody (mAb) that targets sialyl Lewis A (sLea), an epitope on CA19-9. CA19-9 is expressed in over 90% of pancreatic cancer (PDAC) and in other diseases including small cell lung, colon and other GI cancers. HuMab-5B1 when used as a therapeutic agent, designated as MVT-5873, has been studied in patients with pancreatic cancer and other CA19-9 positive tumors. MVT-5873 has recently completed a monotherapy Phase 1a clinical trial in 32 patients. The HuMab-5B1 antibody coupled with a PET imaging agent, designated as MVT-2163, has recently completed a 12 patient Phase 1a clinical trial as well. With our collaborators including Memorial Sloan Kettering Cancer Center, Rockefeller University, Sarah Cannon Research Institute, HonorHealth and Imaging Endpoints, we have treated 50 patients with either our therapeutic antibody (MVT-5873) or our PET imaging diagnostic product (MVT-2163), and demonstrated early safety, specificity for the target and a potential efficacy signal. Data from these two studies have accelerated development of the Company's Radioimmunotherapy (RIT) product, designated as MVT-1075, and patient dosing in a Phase 1 clinical study has commenced for our lead development program which combines the targeting specificity of the HuMab-5B1 antibody with the clinically proven potency of a radionuclide.
Identifying and Recovering the Right Antibodies
We study the protective immune response created by repeated vaccination of cancer patients. Our antibody discovery technology is able to identify and recover the antibodies patients have made from vaccines administered to patients against their cancers. We search for the very best antibodies made, from any patient receiving the vaccine and the best antibody can become our monoclonal antibody development candidate.
Proprietary approach to the discovery and development of novel fully human antibody therapy and diagnostic agents
Products in Development: Radioimmunotherapy (MVT-1075), Therapeutic (MVT-5873), ImmunoPET Imaging (MVT-2163) Diagnostic
Our lead therapeutic program, Radioimmunotherapy (MVT-1075) is currently being evaluated in a Phase 1 clinical study for the treatment of CA19-9 positive malignancies including pancreatic, colon and lung cancers. Interim data analysis from cohort 1 is expected to be completed in the second half of 2017. Therapeutic (MVT-5873) has recently completed a Phase 1a clinical study as a monotherapy for the treatment of pancreatic cancer and other CA19-9 expressing cancers. The topline results from our 32 patient single agent study were presented in June at ASCO and results from our ongoing Phase 1 study in combination with chemotherapy are expected in the second half of 2017. Our diagnostic product, ImmunoPET Imaging (MVT-2163) has also completed a Phase 1a clinical study for diagnosing pancreatic cancer with topline results from our 12 patient Phase 1a presented at SNMMI in June of this year.
Additional details of our clinical programs can be found at www.clinicaltrials.com. Please use the following identifier numbers that are associated with our lead clinical programs:
Partnerships with Leading Research Centers
We are collaborating with several world-class oncology research and patient treatment organizations, including Memorial Sloan Kettering Cancer Center, Rockefeller University, Sarah Cannon, HonorHealth and Imaging Endpoints. We seek to leverage these valuable relationships with leading experts in the field to continue the development of our current products and explore follow-on opportunities.
Contact us if you have questions about our company, antibody based therapeutics or any other questions or comments.